AnaptysBio Inc (ANAB)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO, CA 92121

Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients suffering from generalized pustular psoriasis, or GPP, EGFR-mediated skin toxicity, ichthyosis, hidradenitis suppurativa and acne.

Data as of 2021-07-19 09:39:37 -0400
Market Cap713.515 Million Shares Outstanding27.369 Million Avg 30-day Volume222.274 Thousand
P/E Ratio-23.91777 Dividend Yield EPS-1.09
Price/Sales10.01 Debt to Equity1.04 EBITDA-31.443 Million
Price to Book Value1.87 Forward PE82.24 Enterprise Value333.155 Million
Total Cash380.36 Million Current Debt14.475 Million Gross Profit71.247 Million
BETA0.46782 52-week High/Low35.85 / 13.92 Next Earnings Date2021-08-09 Price to Cash FLow (P/CF) -39.0806
Data provided by IEX Cloud
View SEC Filings from ANAB instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 5 -60.0% 1 (0.06%) 3 (0.17%) -66.67%
Funds Holding: 123 136 -9.56% 43 (2.52%) 54 (3.13%) -20.37%
13F shares: 29.163 Million 27.942 Million 4.37% 15.504 Million 14.03 Million 10.51%
% Ownership 56.6542 51.3023 10.43%
New Positions: 13 22 -40.91% 5 13 -61.54%
Increased Positions 41 36 13.89% 19 10 90.0%
Closed Positions 25 19 31.58% 16 11 45.45%
Reduced Positions 39 45 -13.33% 12 24 -50.0%
Total Calls 301.553 Thousand 191.825 Thousand 57.2% 231.589 Thousand 182.289 Thousand 27.04%
Total Puts 315.243 Thousand 76.707 Thousand 310.97% 52.5 Thousand 41 Thousand 28.05%
PUT/CALL Ratio 1.05 0.4 162.5% 0.23 0.22 4.55%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ANAB (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ANAB BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SURIA HAMZA PRESIDENT, CEO

  • Officer
  • Director
87,997 2021-05-12 2

ECOR1 CAPITAL, LLC

NODELMAN OLEG

  • Director
  • 10% Owner
7,520,424 2021-04-30 3

NODELMAN OLEG

  • Director
  • 10% Owner
7,151,624 2021-04-08 3

ECOR1 CAPITAL, LLC

  • 10% Owner
7,151,624 2021-03-08 3

RENTON HOLLINGS

  • Director
0 2021-02-10 1

SCHMID JOHN P.

  • Director
0 2021-02-10 1

TOPPER JAMES N

  • Director
  • 10% Owner
0 2021-02-10 2

WARE J. ANTHONY

  • Director
0 2021-02-10 1

FENTON DENNIS M

  • Director
0 2021-02-10 1

LOUMEAU ERIC J COO, GENERAL COUNSEL

  • Officer
0 2021-02-10 1

HAMILL LAURA

  • Director
0 2021-02-10 1

MULROY DENNIS CHIEF FINANCIAL OFFICER

  • Officer
0 2021-02-10 1

LIZZUL PAUL F. CHIEF MEDICAL OFFICER

  • Officer
0 2021-02-10 3

MARQUET MAGDA

  • Director
0 2021-02-10 3

LONDEI MARCO CHIEF MEDICAL OFFICER

  • Officer
0 2019-12-06 0

PISCITELLI DOMINIC CHIEF FINANCIAL OFFICER

  • Officer
0 2019-02-08 0

LYDON NICHOLAS

  • Director
0 2019-02-08 0

FRAZIER HEALTHCARE VII, L.P.

FRAZIER HEALTHCARE VII-A, L.P.

FHM VII, L.P.

FHM VII, L.L.C.

FRAZIER ALAN D

NAINI NADER J

EVERY NATHAN R

HERON PATRICK J

  • 10% Owner
No longer subject to file 2018-05-11 0

FRAZIER HEALTHCARE V, LP

FHM V, LP

FHM V, LLC

FRAZIER ALAN D

NAINI NADER J

EVERY NATHAN R

HERON PATRICK J

  • 10% Owner
No longer subject to file 2018-05-11 0

GALLAGHER CAROL GILTNER

  • Director
0 2018-02-02 0

SCHOENECK JAMES A

  • Director
0 2018-02-02 0

NOVO HOLDINGS A/S

  • 10% Owner
No longer subject to file 2017-08-21 0

AVALON VENTURES VII L P

AVALON VENTURES VII GP, LLC

KINSELLA KEVIN J

TOMLIN STEPHEN LAWRENCE

  • 10% Owner
  • SEE REMARKSSEE REMARKSSEE REMARKS
No longer subject to file 2017-07-26 0

MOYLE MATTHEW CHIEF SCIENTIFIC OFFICER

  • Officer
0 2017-02-24 0

AVALON VENTURES VII L P

KINSELLA KEVIN J

TOMLIN STEPHEN LAWRENCE

  • 10% Owner
2,036,932 2017-01-25 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ANAPTYSBIO INC ANAB 2021-07-26 22:15:03 UTC -0.402 0.482 1000000
ANAPTYSBIO INC ANAB 2021-07-26 21:45:04 UTC -0.402 0.482 1000000
ANAPTYSBIO INC ANAB 2021-07-26 21:15:03 UTC -0.402 0.482 1000000
ANAPTYSBIO INC ANAB 2021-07-26 20:45:03 UTC -0.402 0.482 1000000
ANAPTYSBIO INC ANAB 2021-07-26 20:15:04 UTC -0.402 0.482 1000000
ANAPTYSBIO INC ANAB 2021-07-26 19:45:02 UTC -0.2386 0.3186 1000000
ANAPTYSBIO INC ANAB 2021-07-26 19:15:03 UTC -0.2386 0.3186 1000000
ANAPTYSBIO INC ANAB 2021-07-26 18:45:03 UTC -0.2386 0.3186 1000000
ANAPTYSBIO INC ANAB 2021-07-26 18:15:03 UTC -0.2386 0.3186 1000000
ANAPTYSBIO INC ANAB 2021-07-26 17:45:02 UTC -0.2386 0.3186 1000000
ANAPTYSBIO INC ANAB 2021-07-26 17:15:03 UTC -0.2386 0.3186 1000000
ANAPTYSBIO INC ANAB 2021-07-26 16:45:03 UTC -0.2442 0.3242 1000000
ANAPTYSBIO INC ANAB 2021-07-26 16:15:03 UTC -0.2442 0.3242 1000000
ANAPTYSBIO INC ANAB 2021-07-26 15:45:03 UTC -0.2442 0.3242 1000000
ANAPTYSBIO INC ANAB 2021-07-26 15:15:03 UTC -0.2442 0.3242 1000000
ANAPTYSBIO INC ANAB 2021-07-26 14:45:03 UTC -0.235 0.315 1000000
ANAPTYSBIO INC ANAB 2021-07-26 14:15:03 UTC -0.235 0.315 1000000
ANAPTYSBIO INC ANAB 2021-07-26 13:45:03 UTC -0.235 0.315 1000000
ANAPTYSBIO INC ANAB 2021-07-26 13:15:02 UTC -0.235 0.315 1000000
ANAPTYSBIO INC ANAB 2021-07-26 12:45:03 UTC -0.235 0.315 1000000

Current Active Short Positions

Get more info on our International short position coverage here

Holder Issuer Net Short Position Position Date Origin
Advanced Series Trust- AST Academic Strategies Asset Allocation Portfolio ANAB -2900.0 shares, $-62495.0 2021-03-31 N-PORT
BlackRock Funds- BlackRock Global Long/Short Equity Fund ANAB -9180.0 shares, $-214353.0 2021-04-30 N-PORT
PDT Partners, LLC AnaptysBio, Inc. 0.59% 2018-02-07 GERMANY

Short Position History (International Only)

Holder Net Short Position Position Date Origin
PDT Partners, LLC AnaptysBio, Inc. 0.68% 2018-01-25 GERMANY
PDT Partners, LLC AnaptysBio, Inc. 0.7% 2018-01-24 GERMANY

Elevate your investments